Side-by-side comparison of AI visibility scores, market position, and capabilities
AI voice automation platform handling healthcare phone calls — benefits verification, prior auth, and referrals — at scale. San Francisco CA; raised $52M+ (a16z, GV);
Infinitus Systems is a healthcare AI company that automates the high-volume, repetitive phone call work that burdens provider administrative teams. Founded in 2019 and headquartered in San Francisco, California, Infinitus has raised more than $52 million from investors including Andreessen Horowitz and GV. The company's AI voice agent, called Maya, conducts real-time phone conversations with insurance payers to verify benefits, check prior authorization status, confirm referrals, and gather other eligibility information on behalf of healthcare providers.\n\nTraditionally, benefits verification and prior authorization follow-up requires large teams of staff members spending hours on hold and navigating complex phone trees. Infinitus replaces this manual process with an AI agent that operates around the clock, completing calls faster than human agents and capturing structured data directly into provider workflows. Customers include health systems, specialty practices, revenue cycle management outsourcers, and digital health companies that need to scale patient access operations without proportionally growing headcount.\n\nThe platform is designed for interoperability, delivering results through APIs and direct integrations with EHR systems, practice management software, and RCM platforms. Infinitus has processed tens of millions of healthcare transactions and continues to expand the scope of calls its AI can handle, with a roadmap that includes scheduling, referral coordination, and patient-facing outreach.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Infinitus Systems vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.